714 related articles for article (PubMed ID: 33540279)
1. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
[TBL] [Abstract][Full Text] [Related]
2. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
[TBL] [Abstract][Full Text] [Related]
3. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
Front Immunol; 2021; 12():647618. PubMed ID: 33796113
[No Abstract] [Full Text] [Related]
4. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
[TBL] [Abstract][Full Text] [Related]
5. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
Goldman-Yassen A; Lee A; Gombolay G
Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
[TBL] [Abstract][Full Text] [Related]
6. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
[TBL] [Abstract][Full Text] [Related]
7. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
[TBL] [Abstract][Full Text] [Related]
8. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
[TBL] [Abstract][Full Text] [Related]
9. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
[TBL] [Abstract][Full Text] [Related]
10. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
11. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
12. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V;
Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777
[TBL] [Abstract][Full Text] [Related]
13. Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody-associated disease.
Li EC; Zheng Y; Cai MT; Lai QL; Fang GL; Du BQ; Shen CH; Zhang YX; Wu LJ; Ding MP
Epilepsia; 2022 Sep; 63(9):2173-2191. PubMed ID: 35652436
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
[TBL] [Abstract][Full Text] [Related]
15. Modified models to distinguish central nervous system demyelinating diseases with brain lesions.
Chen B; Qin C; Ji S; Tian D; Zhang M; Bu B
Mult Scler Relat Disord; 2021 Jul; 52():102965. PubMed ID: 33905981
[TBL] [Abstract][Full Text] [Related]
16. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM).
Carnero Contentti E; Lopez PA; Pettinicchi JP; Pappolla A; Miguez J; Patrucco L; Cristiano E; Vrech C; Tkachuk V; Liwacki S; Correale J; Marrodan M; Gaitán MI; Fiol M; Negrotto L; Ysrraelit MC; Burgos M; Leguizamon F; Tavolini D; Deri N; Balbuena ME; Mainella C; Luetic G; Blaya P; Hryb J; Menichini ML; Alvez Pinheiro A; Nofal P; Zanga G; Barboza A; Martos I; Lazaro L; Alonso R; Silva E; Bestoso S; Fracaro ME; Carrá A; Garcea O; Fernandez Liguori N; Alonso Serena M; Caride A; Rojas JI
Mult Scler Relat Disord; 2021 Apr; 49():102742. PubMed ID: 33454601
[TBL] [Abstract][Full Text] [Related]
17. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
19. Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis.
Messina S; Mariano R; Roca-Fernandez A; Cavey A; Jurynczyk M; Leite MI; Calabrese M; Jenkinson M; Palace J
Mult Scler; 2022 Feb; 28(2):217-227. PubMed ID: 34048323
[TBL] [Abstract][Full Text] [Related]
20. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
ZhangBao J; Huang W; Zhou L; Wang L; Chang X; Lu C; Zhao C; Lu J; Quan C
Eur J Neurol; 2021 Apr; 28(4):1308-1315. PubMed ID: 33220172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]